Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: A feasibility study

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 3, 1998, Pages 183-193

  Meikle, Steven R ^a   Matthews, Julian C ^b   Brock, Cathryn S ^b   Wells, Paula ^b   Harte, Robert J A ^b   Cunningham, Vincent J ^b   Jones, Terry ^b   Price, Pat ^b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b Postgraduate Medical School   (United Kingdom)

Author keywords

Anti cancer drugs; Drug evaluation; Pharmacokinetics; Positron emission tomography; Spectral analysis

Indexed keywords

5 (3 METHYLTRIAZEN 1 YL)IMIDAZOLE 4 CARBOXYAMIDE; ACRIDINECARBOXAMIDE; ANTINEOPLASTIC AGENT; DRUG METABOLITE; FLUOROURACIL; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ARTICLE; BRAIN; COMPARATIVE STUDY; COMPARTMENT MODEL; DRUG DISTRIBUTION; DRUG SCREENING; HUMAN; ISOTOPE LABELING; LIVER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SPECTROSCOPY; SPLEEN; TECHNIQUE; TUMOR;

ACRIDINES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; COLORECTAL NEOPLASMS; DACARBAZINE; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; GLIOMA; HUMANS; MIDDLE AGED; SPECTRUM ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031847281     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050804     Document Type: Article

References (26)

1. Atwell GJ, Rewcastle GW, Baguley BC (1987) Potential anti-tumour agents. 50. In vivo solid tumour activity of derivatives of N-[2-(dimethylamino)ethyl]aeridine-4-carboxamide. J Med Chem 30: 664-669
2. Bailey DL, Meikle SR (1994) A convolution-subtraction scatter correction method for 3D PET. Phys Med Biol 39: 411-424
3. Brock CS, Matthews JC, Brown G, Luthra SK, Brady F, Newlands ES, Price P (1996) The kinetic behaviour of temozolomide in man. J Clin Oncol 15: 475
4. 11C-methyl]NSC 601316 for pre-clinical evaluation in man by PET. J Labelled Compd Radiopharm 35: 558
5. 11C-methyl]methylisocyanate and application with microwave heating to labelling the novel anticancer agent temozolomide. J Labelled Compd Radiopharm 35: 100-102
6. Chiao P, Fessier JA, Zasadny KR, Wahl RL (1995) Spectral analysis using regularized non-negative least-squares estimation. Conference record of the 1995 IEEE medical imaging conference. San Francisco, 21-28 October 1995, pp 1680-1683
7. Collins JM, Dedrick RL, King FG, Speyer JL, Myers CE (1980) Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharmacol Ther 28: 235-246
8. Cunningham VJ, Jones T (1993) Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab 13: 15-23
9. Cunningham VJ, Bailey DL, Hutton B, Richardson A, Jones T (1991) A practical method for assessing heterogeneity in kinetic PET data. J Cereb Blood Flow Metab 11 [Suppl 2]: S558
10. Cunningham VJ, Ashburner J, Byrne H, Jones T (1993) Use of spectral analysis to obtain parametric images from dynamic PET studies. In: Uemura K, Lasson NA, Jones T, Kanno I (eds) Quantification of brain function. Tracer kinetics and image analysis in brain PET. Elsevier, Amsterdam, pp 101-108
11. Harte RJA (1996) Pharmacokinetic evaluation of anticancer drugs using positron emitting nuclides. MD Thesis, University of Bristol
12. Herholz K, Wienhard K, Heiss W-D (1990) Validity of PET studies in brain tumours. Cerebrovasc Brain Metab Rev 2: 240-265
13. 15O]water and dynamic positron emission tomography. J Cereb Blood Flow Metab 8: 285-288
14. Kinahan PE, Rogers JG (1989) Analytic 3-D image reconstruction using all detected events. IEEE Trans Nucl Sci 36 964-968
15. Lawson CL, Hanson RJ (1974) Solving least squares problems. Prentice-Hall, Englewood Cliffs, New Jersey
16. Matthews JC, Bailey D, Price P, Cunningham V (1997) The direct calculation of parametric images from dynamic PET data using maximum-likelihood iterative reconstruction. Phys Med Biol 42: 1155-1173
17. Paxton JW, Young D, Robertson IGC (1993) Pharmacokinetics of acridine-4-carboxamide in the rat. with extrapolation to humans. Cancer Chemother Pharmacol 32: 323-325
18. Ramachandran GN, Lakshminarayanan AV (1971) Three-dimensional reconstruction from radiographs and electron micrographs: application of convolutions instead of Fourier transforms. Proc Natl Acad Sci USA 68: 2236-2240
19. Ranicar ASO, Williams CW, Schnorr L, Clark JC, Rhodes CG, Bloomfield PM, Jones T (1991) The on-line monitoring of continuously withdrawn arterial blood during PET studies using a single BGO photomultiplier assembly and non-stick tubing. Med Prog Technol 17: 259-264
20. 18F]fluorodeoxyglucose method. J Cereb Blood Flow Metab 12: 823-834
21. Spinks TJ, Jones T, Gilardi MC, Heather JD (1988) Physical performance of the latest generation of commercial positron scanners. IEEE Trans Nucl Sci 35: 721-725
22. Spinks TJ, Jones T, Bailey DL (1992) Physical performance of a positron tomograph for brain imaging with retractable septa Phys Med Biol 37: 1637-1655
23. Stevens MFG, Hickman JA, Langdon SP (1987) Antitumour activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo [5,1-d]-l,2,3,5-tetrazin-4 (3H)-one (CCRG 91045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47: 5846-5852
24. Tilsley DWO, Harte RJA, Jones T, Brady F, Luthra SK, Brown G, Price PM (1993) New techniques in the pharmacokinetic analysis of cancer drugs. IV. Positron emission tomography. Cancer Surv 17: 425-442
25. Tobler HJ, Engel G (1983) Affinity spectra: a novel way for the evaluation of equilibrium experiments. Naunyn-Schmiedebergs Arch Pharmacol 322: 183-192
26. Wells P, Harte RJA, Price P (1996) Positron emission tomography: a new investigational area for cancer research. Clin Oncol 8: 7-14